-
公开(公告)号：US09212168B2
公开(公告)日：2015-12-15
申请号：US13667197
申请日：2012-11-02
申请人： Daniel D. Long , Robert Murray McKinnell , Lan Jiang , Mandy Loo , Kassandra Lepack , Lori Jean Van Orden , Gavin Ogawa
发明人： Daniel D. Long , Robert Murray McKinnell , Lan Jiang , Mandy Loo , Kassandra Lepack , Lori Jean Van Orden , Gavin Ogawa
IPC分类号： C07D405/14 , C07D401/14 , C07D413/14 , C07D409/14 , C07D491/113
CPC分类号： A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D491/113
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20160038483A1
公开(公告)日：2016-02-11
申请号：US14883856
申请日：2015-10-15
申请人： Daniel D. Long , Robert Murray McKinnell , Lan Jiang , Mandy Loo , Kassandra Lepack , Lori Jean Van Orden , Gavin Ogawa
发明人： Daniel D. Long , Robert Murray McKinnell , Lan Jiang , Mandy Loo , Kassandra Lepack , Lori Jean Van Orden , Gavin Ogawa
IPC分类号： A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06
CPC分类号： A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D491/113
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
-
公开(公告)号：US20150071878A1
公开(公告)日：2015-03-12
申请号：US14539039
申请日：2014-11-12
申请人： Robert Murray McKinnell , Daniel D. Long , Lori Jean Van Orden , Lan Jiang , Mandy Loo , Daisuke Roland Saito , Sheila Zipfel , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa
发明人： Robert Murray McKinnell , Daniel D. Long , Lori Jean Van Orden , Lan Jiang , Mandy Loo , Daisuke Roland Saito , Sheila Zipfel , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa
IPC分类号： C07D401/14 , A61K45/06 , A61K31/496
CPC分类号： C07D401/14 , A61K31/496 , A61K45/06 , C07D403/14
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US08921372B2
公开(公告)日：2014-12-30
申请号：US13288216
申请日：2011-11-03
申请人： Robert Murray McKinnell , Daniel D. Long , Lori Jean Van Orden , Lan Jiang , Mandy Loo , Daisuke Roland Saito , Sheila Zipfel , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa , Xiaojun Huang , Weijiang Zhang
发明人： Robert Murray McKinnell , Daniel D. Long , Lori Jean Van Orden , Lan Jiang , Mandy Loo , Daisuke Roland Saito , Sheila Zipfel , Eric L. Stangeland , Kassandra Lepack , Gavin Ogawa , Xiaojun Huang , Weijiang Zhang
IPC分类号： A61K31/497 , C07D401/14 , C07D403/14 , A61P1/16
CPC分类号： C07D401/14 , A61K31/496 , A61K45/06 , C07D403/14
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US09206159B2
公开(公告)日：2015-12-08
申请号：US13869199
申请日：2013-04-24
IPC分类号： C07D401/14 , A61K31/496 , A61K31/506 , A61K31/55 , C07D487/08 , C07D405/14 , A61K45/06
CPC分类号： C07D401/14 , A61K31/496 , A61K31/506 , A61K31/55 , A61K45/06 , C07D405/14 , C07D487/08
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20130287730A1
公开(公告)日：2013-10-31
申请号：US13869199
申请日：2013-04-24
IPC分类号： C07D401/14 , A61K45/06 , C07D487/08 , A61K31/55 , A61K31/496 , A61K31/506
CPC分类号： C07D401/14 , A61K31/496 , A61K31/506 , A61K31/55 , A61K45/06 , C07D405/14 , C07D487/08
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20150183761A1
公开(公告)日：2015-07-02
申请号：US14488520
申请日：2014-09-17
IPC分类号： C07D401/14 , C07D409/14 , C07D405/14
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/5058
摘要： The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明涉及式（I）的苯并咪唑 - 甲酰胺5-HT 4受体激动剂化合物，其中R 1和X如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗与5-HT 4受体活性有关的疾病的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US09428489B2
公开(公告)日：2016-08-30
申请号：US14488520
申请日：2014-09-17
IPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/50
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/5058
摘要： The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
-
9.发明授权公开(公告)号：US08377964B2
公开(公告)日：2013-02-19
申请号：US12796902
申请日：2010-06-09
申请人： Robert Murray McKinnell , Roland Gendron , Lan Jiang , Seok-ki Choi , Daniel D. Long , Paul R. Fatheree , Daniel Marquess
发明人： Robert Murray McKinnell , Roland Gendron , Lan Jiang , Seok-ki Choi , Daniel D. Long , Paul R. Fatheree , Daniel Marquess
IPC分类号： A61K31/4545
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/5058
摘要： The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明涉及式（I）的苯并咪唑 - 甲酰胺5-HT 4受体激动剂化合物，其中R 1和X如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗与5-HT 4受体活性有关的疾病的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20100249186A1
公开(公告)日：2010-09-30
申请号：US12796902
申请日：2010-06-09
申请人： Robert Murray McKinnell , Roland Gendron , Lan Jiang , Seoki-ki Choi , Daniel D. Long , Paul R. Fatheree , Daniel Marquess
发明人： Robert Murray McKinnell , Roland Gendron , Lan Jiang , Seoki-ki Choi , Daniel D. Long , Paul R. Fatheree , Daniel Marquess
IPC分类号： A61K31/4545 , A61P1/00 , A61P1/04
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/5058
摘要： The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明涉及式（I）的苯并咪唑 - 甲酰胺5-HT 4受体激动剂化合物，其中R 1和X如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗与5-HT 4受体活性有关的疾病的方法，以及可用于制备这些化合物的方法和中间体。
-
-
-
-
-
-
-
-
-
搜索结果
129 条记录 (耗时 0.042 秒)
